NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension-Reference-Cited by-同舟云学术

NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension

Published:2001-07-10 Issue:15 Volume:98 Page:8897-8902
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proceedings of the National Academy of Sciences

Author:

Fiorucci S.,Antonelli E.,Morelli O.,Mencarelli A.,Casini A.,Mello T.,Palazzetti B.,Tallet D.,del Soldato P.,Morelli A.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference33 articles.

1. The course of patients after variceal hemorrhage

2. The hepatic circulation in health and disease: Report of a single-topic symposium

3. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver.

4. The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats;Biomedicine & Pharmacotherapy;2024-02

2. Cirrhotic Cardiomyopathy: The Interplay Between Liver and Heart;Cureus;2022-08-13

3. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy;JHEP Reports;2021-08

4. Fluorofenidone protects liver against inflammation and fibrosis by blocking the activation of NF‐κB pathway;The FASEB Journal;2021-06-21

5. Liver-targeted delivery of asiatic acid nanostructured lipid carrier for the treatment of liver fibrosis;Drug Delivery;2021-01-01